tolbutamide has been researched along with ticrynafen in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aoyama, R; Jones, JP; Rao, S; Rettie, A; Schrag, M; Trager, WF | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Dansette, PM; López-Garcia, MP; Mansuy, D | 1 |
Dansette, P; Goldstein, JL; Jean, P; Lopez-Garcia, P; Mansuy, D | 1 |
1 review(s) available for tolbutamide and ticrynafen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
8 other study(ies) available for tolbutamide and ticrynafen
Article | Year |
---|---|
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Topics: Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Ligands; Models, Biological; Models, Molecular; Protein Binding; Reproducibility of Results; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Structure-Activity Relationship; Sulfaphenazole; Sulfonamides; Warfarin | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid.
Topics: Aryl Hydrocarbon Hydroxylases; Cloning, Molecular; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Glutathione; Humans; Kinetics; Microsomes; Models, Theoretical; Recombinant Proteins; Saccharomyces cerevisiae; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Ticrynafen; Time Factors; Tolbutamide | 1994 |
Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Hydroxylation; Isoenzymes; Male; Membrane Proteins; Microsomes; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Recombinant Proteins; Saccharomyces cerevisiae; Steroid 16-alpha-Hydroxylase; Ticrynafen; Tolbutamide | 1996 |